1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Drugs In Development, 2022, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 15, 14, 24, 5, 62, 23 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5 and 1 molecules, respectively.
Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Schizophrenia - Overview
- Schizophrenia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Schizophrenia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Schizophrenia - Companies Involved in Therapeutics Development
- Schizophrenia - Drug Profiles
- Schizophrenia - Dormant Projects
- Schizophrenia - Discontinued Products
- Schizophrenia - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Schizophrenia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Schizophrenia - Dormant Projects, 2022
- Schizophrenia - Discontinued Products, 2022
- Number of Products under Development for Schizophrenia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3Z ehf
- AbbVie Inc
- Acadia Pharmaceuticals Inc
- Adamed Pharma SA
- Adare Pharma Solutions
- Addex Therapeutics Ltd
- AgeneBio Inc
- AgoneX Biopharmaceuticals Inc
- Alexza Pharmaceuticals Inc
- Ananda Scientific Inc
- Anavex Life Sciences Corp
- Athira Pharma Inc
- Autifony Therapeutics Ltd
- Avanir Pharmaceuticals Inc
- Avicanna Inc
- BCWorld Pharm Co Ltd
- Benuvia Therapeutics Inc
- Biogen Inc
- BioXcel Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Celon Pharma SA
- Cerevance Inc
- Cerevel Therapeutics Holdings Inc
- Curemark LLC
- CuroNZ Ltd
- Cyclerion Therapeutics Inc
- Daewoong Pharmaceutical Co Ltd
- Daya Drug Discoveries Inc
- Delpor Inc
- Denovo Biopharma LLC
- Echo Pharmaceuticals BV
- Endosane Pharmaceuticals GmbH
- Entheogenix Biosciences Inc
- Exscientia Plc
- F. Hoffmann-La Roche Ltd
- Gabather AB
- Gedeon Richter Plc
- Genochem SAS
- GP Pharm SA
- H. Lundbeck AS
- Intra-Cellular Therapies Inc
- Io Therapeutics Inc
- Jaguar Health Inc
- Jazz Pharmaceuticals Plc
- Jiangsu Enhua Pharmaceutical Group Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Nhwa Pharmaceutical Co Ltd
- Johnson & Johnson
- Karuna Therapeutics Inc
- Laboratorios Farmaceuticos Rovi SA
- LB Pharmaceuticals Inc
- Lead Discovery Center GmbH
- Livzon Pharmaceutical Group Co Ltd
- Lohocla Research Corp
- Luye Pharma Group Ltd
- Lyndra Therapeutics Inc.
- Malachite Innovations Inc
- MapLight therapeutics Inc
- MedinCell SA
- Mental-Heal Ltd
- Merck & Co Inc
- Midatech Pharma Plc
- Mitsubishi Tanabe Pharma Corp
- Nanomi BV
- Neonc Technologies Inc
- Neumora Therapeutics Inc
- Neurelis Inc
- Neurocrine Biosciences Inc
- NeurOp Inc
- NeuroSolis Inc
- Newron Pharmaceuticals SpA
- Nostrum Biodiscovery SL
- Novartis AG
- Omeros Corp
- Oryzon Genomics SA
- Otsuka Pharmaceutical Co Ltd
- OWP Pharmaceuticals Inc
- Pasithea Therapeutics Corp
- ProMIS Neurosciences Inc
- Ra Pharmaceuticals Inc
- Reviva Pharmaceuticals Inc
- Saniona AB
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Zhongze Medicine Tech Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Siragen Pharmaceuticals Inc
- Sirtsei Pharmaceuticals Inc
- SkySea Pharmaceutical Inc
- Sosei Group Corp
- Sumitomo Pharma Co Ltd
- Sunovion Pharmaceuticals Inc
- Suven Life Sciences Ltd
- SyneuRx International (Taiwan) Corp
- Taho Pharmaceuticals Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Co Ltd
- Terran Biosciences Inc
- Teva Pharmaceutical Industries Ltd
- The Greater Cannabis Company Inc
- Therapeutic Solutions International Inc
- Valentec
- Vanda Pharmaceuticals Inc
- Verge Genomics
- Vivozon Inc
- Whan In Pharm Co Ltd
- YaoPharma Co Ltd
- Yoda Pharmaceuticals Inc
- Zhejiang Jingxin Pharmaceutical Co Ltd
